Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
08 mai 2024 07h02 HE
|
Olema Oncology
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
11 déc. 2023 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
11 déc. 2023 04h00 HE
|
AKAMPION
HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
24 oct. 2023 04h00 HE
|
AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
23 oct. 2023 08h12 HE
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology...
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
23 oct. 2023 03h00 HE
|
Medigene AG
Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell...
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
22 oct. 2023 02h55 HE
|
Olema Oncology
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with ESR1 mutations at baseline, the median PFS was 5.6 months with a CBR of 52% In an analysis...
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
22 oct. 2023 02h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
ESMO 2023 Coverage: Get real time insights and analysis with DelveInsight
20 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- ESMO 2023 Coverage: Get real time insights and analysis with DelveInsight The ESMO conference stands as a pivotal event in the oncology sphere,...
Correction: ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
18 oct. 2023 15h50 HE
|
ImCheck Therapeutics SAS
ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety...